COVID-19 vaccination, treatments for rheumatic disease and more—the Late-Breaking Abstracts session of ACR Convergence 2021 highlighted six studies with implications for rheumatology.
Search results for: hospital
How Do Axial SpA & PsA with Axial Involvement Differ?
The differences between axial spondyloarthropathy (axSpA) and axial involvement in psoriatic arthritis (axPsA) have clinical and therapeutic implications. Three experts discussed the distinctions during ACR Convergence 2021.
New Data Highlight Effectiveness of Guselkumab for Patients with PsA
The use of guselkumab improved joint and skin symptoms in biologic naive patients with PsA, according to research presented during ACR Convergence 2021.
Tigulixostat Appears Promising for the Treatment of Gout
In a phase 2 study, tigulixostat treatment proved safe for lowering serum uric acid (sUA) levels in patients with gout.
FDA Approves Secukinumab for Children with Enthesitis-Related Arthritis & PsA
The FDA has approved the use of secukinumab for pediatric patients with enthesitis-related arthritis and psoriatic arthritis, after research showed a longer time to disease flare than placebo.
The Ins & Outs of ILD: The Management & Treatment of ILD in Patients with Rheumatic Disease
Melissa Griffith, MD, discussed the diagnosis and treatment of interstitial lung disease (ILD) in patients with rheumatic diseases, including connective tissue disease and more.
ACR Town Hall Provides Update on Oral Antiviral Therapy for COVID-19
At an ACR COVID-19 town hall on COVID-19, infectious disease experts discussed the most up-to-datecurrent information on pre- and post-exposure monoclonal antibody therapy, oral antivirals and vaccines for rheumatology patients.
Key 2022 Coding & Billing Updates
In 2022, rheumatology practices should prepare for documentation, coding, billing and reimbursement revisions related to evaluation and management (E/M), split/shared billing policies and telehealth services.
ACR Insurance Subcommittee Chair Encourages Member Engagement
Rheumatology practices have a voice in payer advocacy through the Insurance Subcommittee of the ACR’s Committee on Rheumatologic Care.
Insights into JAK Inhibitor Use
According to a German study presented during ACR Convergence 2021, treatment persistence with JAK inhibitors is comparable to TNF inhibitors and other bDMARDs among patients with rheumatoid arthritis.
- « Previous Page
- 1
- …
- 48
- 49
- 50
- 51
- 52
- …
- 318
- Next Page »